Alexion Collaborates with Caelum Biosciences for its CAEL-101 to Treat Light Chain (AL) Amyloidosis

Shots:

• Alexion and Caelum collaborate for the development of CAEL-101 in PIa/Ib trial and Caelum to receive $60M as an equity investment, near-term milestones & will conduct P-II trial for CAEL-101 to treat Light Chain (AL) Amyloidosis
• Post-P-II study completion, Alexion will get an exclusive option to acquire Caelum, depending on the results of CAEL-101 in P-II. If the option is exercised, Caelum will receive $500M, including upfront, milestones, and royalties from Alexion
• CAEL-101 is a mAb, targeted for reducing and eliminating amyloid accumulation in patients with AL, has received FDA’s ODD for AL amyloidosis has shown improved results in P-Ia/Ib study for patients with r/r AL amyloidosis

Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire